{"ticker": {"uuid": "9c44c245-65f3-492b-bf15-2ea6b899e404", "symbol": "BHVN", "name": "Biohaven Ltd.", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Price to earnings forward of Biohaven Ltd. \u2013 BOATS:BHVN", "summary": "This page provides financial information for Biohaven Ltd. (BHVN), specifically focusing on its forward price-to-earnings ratio. It is hosted on TradingView, a platform offering market data, financial tools, and community features for traders and investors.", "url": "https://www.tradingview.com/symbols/BOATS-BHVN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T19:13:22", "published_display": "14 Jul 2026 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Research Ltd Shs Unsponsored Brazilian Depositary Receipt Repr 0.33333333 Shs", "summary": "The article focuses on the \"Price to book forward\" for Biohaven Research Ltd Shs Unsponsored Brazilian Depositary Receipt Repr 0.33333333 Shs (BHVN34) traded on B3. It displays the stock's ticker, current market status, and various financial and technical data sections available ", "url": "https://www.tradingview.com/symbols/BMFBOVESPA-BHVN34/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T01:39:04", "published_display": "14 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk (NYSE:BHVN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYzl0WGhENFJOdFdhQUFBT3o4ZjN6RDFUNWtWbXd0RnJOSVZwT0pxamF5cFNWaTBJZTMxQThGWjFvLTIzOGU2VG5jaUhtZG5FajQtaERab29hYkZkUTNsZXVFNVJ5WTJuUTRjdHpuWHhndmgxOFV2Tl83MHBIT0pUc0NadW5uQ004N0VWZlZhRWg0UXpTUWRnVUJrUDdWbVFxRk5Gd2dn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-13T12:17:31+00:00", "published_display": "13 Jul 2026 12:17", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Biohaven Ltd. \u2013 BOATS:BHVN", "summary": "This article provides financial information for Biohaven Ltd. (BHVN), specifically its enterprise value to EBIT forward. It indicates various sections typically found on financial platforms, such as an overview, financials, news, and community features, but the core content only ", "url": "https://www.tradingview.com/symbols/BOATS-BHVN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T18:39:16", "published_display": "12 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (BHVN) Advances Key Trials Following Pipeline Progress While Valuation Still Looks Pricey", "summary": "Biohaven (BHVN) has reached two significant clinical milestones, completing enrollment for its RISE3 opakalim epilepsy trial and initiating Phase 3 testing for BHV-1300 in Graves' disease, leading to a recent surge in its stock price. Despite this positive momentum and a 51.4% 30", "url": "https://www.sahmcapital.com/news/content/biohaven-bhvn-advances-key-trials-following-pipeline-progress-while-valuation-still-looks-pricey-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T14:09:39", "published_display": "11 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Biohaven Ltd. \u2013 NYSE:BHVN", "summary": "This article presents financial information focused on Biohaven Ltd. (NYSE: BHVN), specifically its enterprise value to revenue forward ratio. It appears to be a financial data snippet from TradingView, indicating no current trading activity as the market is closed.", "url": "https://www.tradingview.com/symbols/NYSE-BHVN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T02:40:48", "published_display": "11 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BHVN News | BIOHAVEN LTD (NYSE:BHVN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE5pRFBqVk9LODZlUWxMVXJlN3RSMllQeWFFLXdFclAyZEQxQjc5NVFod1NCMEo4VTNlQy1SN1VQR2htQW9oekx1SzVxNHVwU1NfTXFmSGtUZHh2d2s?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:04:00+00:00", "published_display": "11 Jul 2026 00:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership", "summary": "", "url": "https://finance.yahoo.com/m/74f0a4dc-902c-3d10-9ac6-dc1f5bc01abe/arpa-h-puts-%24160m-into.html", "source_name": "BioPharma Dive", "published_at": "2026-07-10T08:04:00+00:00", "published_display": "10 Jul 2026 08:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Biohaven\u2019s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/biohaven-bhvn-r-d-shake-061150596.html", "source_name": "Simply Wall St.", "published_at": "2026-07-10T06:11:50+00:00", "published_display": "10 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Chief Scientific Officer Bruce Car to Transition to Chief Innovation Officer", "summary": "Biohaven Pharmaceutical Holding Company Ltd. announced that Bruce Car, Ph.D., will transition from Chief Scientific Officer to Chief Innovation Officer. In his new role, Dr. Car will focus on external pipeline innovation, business development, and strategic partnerships, while al", "url": "https://www.moomoo.com/news/post/72736474/biohaven-chief-scientific-officer-bruce-car-to-transition-to-chief", "source_name": "Moomoo", "published_at": "2026-07-09T23:39:22", "published_display": "09 Jul 2026 23:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven reshuffles scientific leadership as Car steps back", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOVGxJck4xX2p4NU5nNmJ2OVYyYTRTXzlsSDd2UWFaMUdUY1ZaSTBJMGRfWHlTM0FvdGZrX0ljdmJjZWFCV09OV3Uzc3JDSVJELVF2NVE2bTVnMDFSd1p4RnAzNU9GaUptNU8zaGp3VzBuSG5sVlRtRXlzOXdJQ0RzT1J0VElEcm9JWUxFU3VzbVdQYjhhUmVURWEyRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T21:00:00+00:00", "published_display": "09 Jul 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janus Henderson holds 8.58M Biohaven shares (BHVN) \u2014 5.7% stake", "summary": "Janus Henderson Group Ltd. has filed an amended Schedule 13G/A, reporting beneficial ownership of 8,584,676 common shares in Biohaven Ltd. (BHVN), which constitutes a 5.7% stake as of June 30, 2026. The filing clarifies that Janus Henderson and its affiliated asset managers exerc", "url": "https://www.stocktitan.net/sec-filings/BHVN/schedule-13g-a-biohaven-ltd-amended-passive-investment-disclosure-c0dc83bc6806.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:39:47", "published_display": "09 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven announces leadership changes in discovery unit By Investing.com", "summary": "Biohaven Ltd. has announced leadership changes within its scientific discovery unit. David Pirman has been promoted to Executive Vice President and Head of Discovery, while Bruce Car is transitioning from Chief Scientific Officer to a part-time Chief Innovation Officer role. The ", "url": "https://ng.investing.com/news/stock-market-news/biohaven-announces-leadership-changes-in-discovery-unit-93CH-2593973", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T21:39:22", "published_display": "09 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Announces Scientific Leadership Transitions", "summary": "Biohaven Ltd. has announced scientific leadership transitions to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, leading internal drug-discovery. Bruce Car, Ph.D., is transitioning f", "url": "https://www.prnewswire.com/news-releases/biohaven-announces-scientific-leadership-transitions-302822263.html", "source_name": "PR Newswire", "published_at": "2026-07-09T21:12:10", "published_display": "09 Jul 2026 21:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (NYSE: BHVN) shifts CSO to innovation role, promotes discovery head", "summary": "Biohaven Ltd. (NYSE: BHVN) has announced significant scientific leadership changes. Bruce Car, Ph.D., will transition from Chief Scientific Officer to a part-time Chief Innovation Officer role, focusing on scientific initiatives and external collaborations, including those with B", "url": "https://www.stocktitan.net/sec-filings/BHVN/8-k-biohaven-ltd-reports-material-event-0e812e6f68dd.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:12:10", "published_display": "09 Jul 2026 21:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Biohaven Announces Scientific Leadership Transitions", "summary": "Biohaven Pharmaceutical Holding Company Ltd. announced significant transitions in its scientific leadership. Dr. Stephen Hoffman, Chief Medical Officer, is retiring and will be succeeded by Dr. Richard Rodgers. Additionally, Dr. Vlad Coric has been appointed as the Chief Scientif", "url": "https://www.moomoo.com/news/post/72735791/press-release-biohaven-announces-scientific-leadership-transitions?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T20:39:22", "published_display": "09 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (BHVN) Completes Enrollment in RISE3 Trial", "summary": "Biohaven (BHVN) has announced the completion of enrollment for its RISE3 trial, a pivotal Phase 2/3 study for opakalim in refractory focal epilepsy, with top-line results expected in the second half of 2026. The company also initiated a Phase 3 trial for BHV-1300 to treat Graves'", "url": "https://finance.yahoo.com/healthcare/articles/biohaven-bhvn-completes-enrollment-rise3-104059634.html", "source_name": "Market source", "published_at": "2026-07-09T10:40:44", "published_display": "09 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (BHVN) Is Up 5.6% After Advancing Two Late-Stage Trials in Epilepsy and Graves\u2019 Disease", "summary": "Biohaven (BHVN) has seen a 5.6% increase after advancing two late-stage trials: completing enrollment for its Phase 2/3 RISE3 trial of opakalim for refractory focal epilepsy and dosing the first patient in a Phase 3 trial of BHV-1300 for Graves\u2019 disease. These milestones highligh", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/biohaven-bhvn-is-up-56-after-advancing-two-late-stage-trials/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-08T21:39:47", "published_display": "08 Jul 2026 21:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Wall Street Is Growing More Cautious on Biohaven (BHVN)", "summary": "Wall Street is showing increased caution towards Biohaven (BHVN) due to mixed analyst sentiments. While BofA downgraded the stock and lowered its price target, citing concerns over its Kv7 epilepsy program and competitive landscape, Deutsche Bank raised its price target and maint", "url": "https://www.insidermonkey.com/blog/why-wall-street-is-growing-more-cautious-on-biohaven-bhvn-1796023/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-07-06T13:20:00", "published_display": "06 Jul 2026 13:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in BHVN Response", "summary": "This article analyzes Biohaven Ltd. (NASDAQ: BHVN) using AI models to suggest trading strategies. It highlights strong near to mid-term sentiment but a weak long-term outlook, identifying compelling upside potential due to a lack of resistance levels above the current price. The ", "url": "https://news.stocktradersdaily.com/news_release/98/Discipline_and_Rules-Based_Execution_in_BHVN_Response_070626032802_1783322882.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T03:28:00", "published_display": "06 Jul 2026 03:28", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BHVN - Biohaven Ltd Latest SEC Filings", "summary": "This article provides the latest SEC filing details for Biohaven Ltd (BHVN), including its stock performance, key financial metrics, insider and institutional ownership, and valuation ratios. The company has a market cap of $2.40 billion and shows significant institutional owners", "url": "https://finviz.com/stock?t=BHVN&ta=1&p=d&ty=lf&b=1&r=m1&page=8", "source_name": "Finviz", "published_at": "2026-07-03T22:41:52", "published_display": "03 Jul 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Shares Drop 9.8% to $14.28", "summary": "Biohaven's shares fell 9.8% to $14.28, following a downgrade from BofA to Underperform with a reduced price target of $11, citing a bearish view on the risk-reward ahead of Phase 3 data for their kv7 epilepsy drug. This contrasts with a Deutsche Bank upgrade to a $20 price target", "url": "https://intellectia.ai/news/stock/biohaven-shares-drop-98-to-1428", "source_name": "Intellectia AI", "published_at": "2026-07-03T22:41:52", "published_display": "03 Jul 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Advancing Opakalim and BHV-1300 to Pivotal Trials Change The Bull Case For Biohaven (BHVN)?", "summary": "Biohaven has advanced two key pipeline assets, opakalim for refractory focal epilepsy and BHV-1300 for Graves' disease, into pivotal trials, marking important milestones for the company's neurology and immunology pipeline. While this progress keeps the programs on track for poten", "url": "https://www.sahmcapital.com/news/content/does-advancing-opakalim-and-bhv-1300-to-pivotal-trials-change-the-bull-case-for-biohaven-bhvn-2026-07-01", "source_name": "Sahm", "published_at": "2026-07-01T19:44:00", "published_display": "01 Jul 2026 19:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out", "summary": "Bank of America Securities downgraded Biohaven Ltd. to Underperform, lowering its price target to $11 from $12. The downgrade stems from concerns about Biohaven's lead epilepsy drug, Opakalim, which is expected to face significant competition from Xenon Pharmaceuticals' azetukaln", "url": "https://www.sahmcapital.com/news/content/analyst-warns-biohavens-lead-drug-may-struggle-to-stand-out-2026-06-29", "source_name": "Sahm", "published_at": "2026-06-30T23:40:21", "published_display": "30 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven's epilepsy drug Opakalim finishes pivotal study enrollment", "summary": "Biohaven Ltd. (NYSE: BHVN) has completed enrollment in its pivotal Phase 2/3 RISE3 study for opakalim, a selective Kv7.2/7.3 activator, aimed at treating refractory focal epilepsy. Top-line results are anticipated in the second half of 2026. The company reported promising data fr", "url": "https://www.stocktitan.net/news/BHVN/biohaven-completes-enrollment-in-rise-3-pivotal-focal-epilepsy-study-p7stx3rq4msv.html", "source_name": "Stock Titan", "published_at": "2026-06-30T15:39:14", "published_display": "30 Jun 2026 15:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven completes enrollment in opakalim epilepsy trial", "summary": "Biohaven Ltd. has completed enrollment in its pivotal Phase 2/3 trial, RISE3, for opakalim, a treatment for refractory focal epilepsy, with top-line results expected in the second half of 2026. The company's stock has surged 32% in the past six months, reflecting optimism about i", "url": "https://www.investing.com/news/company-news/biohaven-completes-enrollment-in-opakalim-epilepsy-trial-93CH-4767573", "source_name": "Investing.com", "published_at": "2026-06-30T12:10:50", "published_display": "30 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven completes enrollment in focal epilepsy drug trial", "summary": "Biohaven Ltd. has completed enrollment in RISE3, a pivotal Phase 2/3 trial for opakalim, an investigational drug for refractory focal epilepsy. Top-line results for this study are anticipated in the second half of 2026. This development marks a significant step forward in the opa", "url": "https://www.streetinsider.com/Corporate+News/Biohaven+completes+enrollment+in+focal+epilepsy+drug+trial/26709571.html", "source_name": "StreetInsider", "published_at": "2026-06-30T11:10:51", "published_display": "30 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12", "summary": "BofA Securities has downgraded Biohaven Pharmaceuticals' rating from Neutral to Underperform. The firm also adjusted its price target for Biohaven, lowering it to $11 from $12. This revision reflects a more cautious outlook on the pharmaceutical company's future performance.", "url": "https://www.moomoo.com/news/post/72190363/update-bofa-securities-downgrades-biohaven-to-underperform-from-neutral-trims?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-30T11:09:45", "published_display": "30 Jun 2026 11:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target", "summary": "BofA Securities has downgraded Biohaven Pharmaceuticals' rating from Neutral to Underperform. The firm has also set a new price target of $11 for Biohaven's stock. This downgrade suggests a negative outlook on the company's future stock performance by BofA Securities.", "url": "https://www.moomoo.com/news/post/72189012/bofa-securities-downgrades-biohaven-to-underperform-from-neutral-11-price", "source_name": "Moomoo", "published_at": "2026-06-30T10:40:20", "published_display": "30 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator", "summary": "Biohaven Ltd. has announced the completion of enrollment in RISE3, a pivotal Phase 2/3 study for its selective Kv7.2/7.3 channel activator, opakalim, for refractory focal epilepsy. Top-line results are anticipated in the second half of 2026. This study aims to provide a new treat", "url": "https://www.prnewswire.com/news-releases/biohaven-completes-enrollment-in-rise-3-pivotal-focal-epilepsy-study-with-opakalim-a-selective-kv7-27-3-activator-302813944.html", "source_name": "PR Newswire", "published_at": "2026-06-30T07:30:50", "published_display": "30 Jun 2026 07:30", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (BHVN) Shares Decline Nearly 10% Amid Market Fluctuatio", "summary": "Biohaven Pharmaceuticals (BHVN) experienced a significant 9.8% stock decline on June 29, 2026, dropping to $14.28, reflecting market volatility and challenges for the clinical-stage biopharmaceutical company. The company has a low GF Score\u2122 of 30/100 and a low profitability rank,", "url": "https://www.gurufocus.com/news/8936400/biohaven-bhvn-shares-decline-nearly-10-amid-market-fluctuations?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-29T22:39:35", "published_display": "29 Jun 2026 22:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at BofA", "summary": "Biohaven Pharmaceutical shares have dropped due to concerns over its Phase 3 trial results for taldefgrobep alfa in spinal muscular atrophy (SMA). BofA Securities downgraded Biohaven from Buy to Neutral and lowered its price target to $30, citing the trial's failure to meet its p", "url": "https://www.moomoo.com/news/post/72206040/biohaven-shares-down-as-phase-3-trial-concerns-trigger-downgrade?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-29T21:10:50", "published_display": "29 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 25, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Going On With Biohaven Stock Monday? - Biohaven (NYSE:BHVN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNNEVNTzhiZHE3MmtDdHVaMVJqOHl5V2VUTUxuZUNGcVFNYS0yR3dpbExqM0hnbjd2OE5KQmhQV29ZTndITkFWZXJFOHdTN3Vja2NsR3NSLWlqRG93SUdwUzB5RGZJQ0lsb1c3SE00UHJqM2tsZG5PMlYyNV9HcDRIN0NybmpJQ3kzb043Y3JuejRlQmJ1RW9aVHlKcjIyQ3JBZEFJcDFIcFdtRjRySFFsX1pqNWhoTkFaMGlteXBiZkpVdjN3clM1d0NCWVo?oc=5", "source_name": "Benzinga", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven's BHV-1300 targets the root cause of Graves' disease in Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOMFRocTBWOUozeWpxRFhvUXhjSE55TmlNNjlrTGFLUTlNWHlUOEdFY2M1amdjZ3VPZC11YXo1NmFJYW9lMXVOY1JEZE9mVzdoRzZJWmpRZmJWR2VKMXhURVB5QWF3d1RXMXVlaU1nSDllekZQQnhUeVNTMFlScEhTbTFURTRfTUxva3F2VWlWWEp4T1RiX2kxcGRrb2xvMGJkYXFSRUM5MFVSYXNFRG1EWHlfMG1jZzE3YWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (BHVN) Climbs 14% Higher Ahead of New Clinical Trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOVXVFcVNvQlg2TDQ2anhEQUc3SEYxZFpNZG1kN3lGT3NJUWVNeHlTWUxsRUVSa0dVYXppaEJxSnJ4V2t4RlNQMUs2MzNOUVd6TVlSR2hCeXYxMllLWnQ5NTVrOWd1ZlB3RVJWZ0k1NDVWOURESEtEa2tFRGpwNmJQQWhjLVZHYTQ4ZC1Yb0lEMFVUT2tXY2c?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (BHVN) Climbs 12.66% Ahead of Pipeline Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQSmxoRDM4TU1pR2NIWGhjWHNCWDRvZ2JJVnZkcUdTSmVETGF6cWVPNzJCbXVaanhsSDVxQmNxaHBIanZ2RDMwZnZDMHNheEQ2ZGZVUFBnbnQ4Y0pYN1JzY2NEcWxhSW9hZlhSaWFXcy1EOXRzRThfU3B4TWZGaEtMdlZ2Yjl0WVEzNTFFOTB3WkE?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Biohaven (BHVN) the Best Stock That Have the Potential to Rise 1000%?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOR3RXZHpfY0ZNTGJYdzdPdjlpY1dOQzJIemtDMjBENG5uWmkxVUtkTUd3WjNvOWdnczNfamhMWDR1dlVUdEFUUnN1WkQ0MjNfRTBYMTZQOVNwc1dDdllhUTNOSjZoVmU2TmZRd1ZrMXVPcTROLVVTUGUzbmpxVjUydVdMX0RiTm5kbUdSaG4tOVhfZ1NZOGZ5WkhTdXN0TTRn?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental brain drug from Biohaven triples glucose use in human donor brains", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQd2wtWkV0WERJZi1XRUFROEIxakN2eDlfbVRYRlpvdzBsREk4dHgtOTdlaU5pZk0tT2ViVHo4cGRjOFBDdVVmV0E0TUp5aVIwRzNieEVPVFJZQVhqYkpySXBtWF93aGtOSmhDRUg1UmZ4elBrRWVTNF9PTHNGTXdTZlJxT3BabUNFMnBIbnkwbHAyV1FxODEyVmM1SWVqLWFFZm91WU54MHNabGoxV2NTNWFVdGp1c1ptRUJROQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwJBVV95cUxORTBwNkkzd0NjamJZSkI5Mmpudndaa0thN1JndnVySDhWMnJ0WGFhWTRUMEJzb1o1aE8yMWZKQ1UzWXpmaHFrczFNb3JILWN1aWFJc3RlWkpMaWtUNGtzU3BISWRLSEJURjZZX01sZTZjQ1M1dGd6Zi1ndGxHeEdyVFFSdzRQWEJ1Z05Vdm9aRU5SY21QV3BkYldJQkVGU0M2TXhDakNzenBHYzUyc1ZpaklrYnNJT0hadmpIaVh4R1NxY0g4MWlsU24zRENlQzNBOXZKREtORW5pX0ZyWUQ3NENBNEE0RFZuc3lfdjNHZHYwT0twc29vUUFUVFJzNHc5b0FRZFEwdlRDT28?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNSnE1UGI2LWdPamFoX1FrdnJGLUtMVERyUVZIaFBfaC1EOUtPXzkxbEN4WXpxLU1nNGdJSWt2M1BCVjdDQVpwNVlxbWhtTVZzbjlmWGNhQzhENGpQeWNYMGJZR1JTelBOaTM3aTRXMEF1WnBOSjgzbDlMVmMyV25pSElGY0lCMU9iUVl2LWZ1ZXhVLUZTR05VOV9kdFRRZzdob2hEdXNBelhvZEZSa2dWMHJzMnZZcnY1LVVkNEFmY3JLaWhQdkcxSTdGT2tNeVJIMGtaSERwUWlPQQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (NYSE: BHVN) shareholders back directors, auditors and pay plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNdGUzc3R6b1F2T2pRTkptSHhYd3RnQTRRT1QxaFd6QV9zd0ZMRnZmRUxQcEtLUUgtYnkyeEpncHZQM29nUjhZRXZDM0NMVVFSV0d2a3JnMmwzdm1DaWhlanVPaksxSlpQbVVmbHVXdHJwTGZOSXJNVnZOYmhxN1J1UVFvT0xJOU5CSFNPd2UycGRjWWZ3a01sdVpsRHFvdVgyWjUw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (BHVN) director granted 68,693 options at $9.61 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOLXNaX3p4QTBjOUs3VHBzVHlRSWVURkdocGU5bGphOXVKdEt1VmhMWVQtREtrTlA2QmdCMWpWWlNIY1FNcWViLVRqaVJrQUdNak9DeWFOSTBkV196eWl3akFfT1JKU3JZZVRhS1NWby1zdjJfbG5vdFB6UVpXWkZfY0Q5LUtrOVJhN25QdHEzaFlpNGVfLV9LNzUtQWJlc0Q4M3BocFMzQlRDQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOZ3hWSDhsWWFBOHN6NTdUNEtDekNUQXlLb2JnMFdGV081YWhCNTYxOEwwNnlJdU5XdG5LeVh6VGlKbkxoTS1VelQ4cW4xZDBSSTNqUFEtLXV1eWo5bFBRWTJpTjQ0V2lyWng5NXpwbEFUYUhUWDRLS3V4MVRmNWVBaGFMOGNxU2FvaVltSjlJQ1h4NnZzNDJ5cmtaMEJ6MWIxOVItX25FWlFtd2NBOVk4?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQZC1BU1JHcWhsdmkwNzM2YkoyTjRtV1d5U2hoa3FtU2w4ZXFFaW0zYWVVcFNwME4tMHFBampOU2hNOVNua0dzdU9XX2g3bGxneUg5Yzh5NVZyZGQxTmF0Ui02Wm5kc2l2ZEhhVnBvZ2JTYzBJdXA2MExTUUd4WTAycXpJRUt2UkVJYnJzbFFxRE5YZlRmYXRuUUhHaHlYRWNBekNmeUpJTDZKd1lPSXJlU1h0R2tBWTc1RC1XWTFSRWVsNU11Yk5RZzZldWJ3TGxVZkxv?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven stock rises as obesity trial completes enrollment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQRm84TFNJZURCUVVpNTNFWUd3TGRmZEdTREtvNHF3NEJjak1IUVRDLTI4V3BhalNKS21tel9RTTJabXcyeUl4dWFLR2w5Nk5RQWNlcFZ0WV9fTF9nNjYzN2NkcENwNE9sUmpCbVp5YV9KRmM0N2tGVGwtNU54MUdWa3NjMS1PZktSYkVBdHZPN2ZJVURkc1IyZnRxSm9qalBVREJJMlo3ZWFJOTJ4bjVBTXhJcXh4UVo1cTB2Yg?oc=5", "source_name": "Investing.com", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (NASDAQ: BHVN) director reports gifting 34,684 shares, adds family trust", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNNFl1cXA1eXhUdl9SR04xSTQ5YUJoc1Bob2Vwbmdhd1NEVDlFSjE3WWxTbzZieF8zUzlXY3ZCZW54dVNZdUJYaGxBNzN5Sk1aTEhaNFpfTTkxZkRpdUZidTYySDQwNUZlbjFHZUtBZmN2OTRRQ3N4SS1vWDF2V0VFeDU4TUZYeThDX3ZzcXF5VE9WS2h4UXVRcTZkaFBma3d5TGdhYy1teVF4UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Ltd. (BHVN) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE55cFJ4ZVpSWEJjU01jUFRfSnVFNzlWUjloNWlQWV9Ib2ZlX19SdXlac2RtUWsydFVtdFhhbWRyYThiSnlEM3FPVWZ5dmJhWGQxTk14YzhLUQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T00:24:09+00:00", "published_display": "13 Jan 2026 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Stock Slumps After Hours As Failed Depression Study Adds To A Brutal 2025 \u2014 Retail Eyes Epilepsy And Obesity Catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQYmJQSFZHVmRrVlJCZjREVEc0RkVsdG04Mzh3ZDhNNy1xY0hiUUN5QVVjaEFtYVlsaDN5dnJXVmZzMlVaWE9PUnEzV3hhb21LVXlLUTFDNWxjMTZmaFRJVzB4d2YtM2NKS3JHcXhMQ195RHlCdUhqTVc0QjdvWXRNbHVwXy1NUVR0SUp1ZU5DYTN6V1F6RnByQVUxZ0ZrNTBkeXIydFJJVGdUVkx4NW4tZHhzQl9ad1FVbXJDTVhkQ1Z5MXlMVk9RbEJBdS1ydVdpVzhabEhFaDh0M2ZL?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQcXgzWGpuYlhmbmpBMWEweWtkYWhEOFNFcXVaNTJnUFJoMW5udkNIVExyRFR0VTQ1QjRFa0F3UWRNc19VQWlFWjhLUk5WMzBPa3ZzYndZSTZiMVpiUWlQSzJFc2tSdEZGOHh2eWdhVnFPekNEc205djdpZ1JRXzdlR29Tdi1OU2dOcWFzM21sd1ZLNkhibmFtTzdZR2t0NnR0SUpaV01vREhUTUhLRG93d0poS0FHelFJM2FSY0duRG9HUmxtZUpjQzEzVHlpUGZJYkozME5SX3M4UQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxONTh3Mkg2aHB1LXluTDRiMzRWbzRuUE9fY0pYUU1tbExITVN6TGdtdW1UN0JOWkFQV2kzM1FQNjZEdU10bHpxbmJBZzB6YnE4WUExcHpYTW1TZGZKSDdFdUtPa1JrdlE3NzRUSmlTVk95dGN1a1l6VXp6dDFWOUx3THBISnlMbWxKWW9wY3NjNng0ZXQ3WGU2TDQzUHJHLWNucVJNblRnMmtjaGNmY1NPUmJHLTJqZmpQWm1XYzZlemN4eVZ1cjVmQzhGY0loLXpWeExpU0ZUay1Sazl3RWVobW84YVYweUJkWG92WGJXbjVpODdRRUlYSDdkYWsyVFI0RGlN?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-04T08:00:00+00:00", "published_display": "04 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQQWhCam45ekN5dksxcFJfR0RnYlpJTFJwWHM2UmFGbVhTZklzYy0zYVFuTVdqQmxXQVM0aGpwckFYV2lLZ3A1TEtxd3NHQUdmdUtseDNqYS1RUzQ0V0djTUwxQnRiTnY4NUR2V0VlMnZoek45UGxGejc1ekZWbG5DN0NWNlMwRkhzTDIxX2RRbi1yWW5lTkZ4WnpkRkU4ZWlwcTQyZ0lnSi1sX3lZVUFad0d3S2dFOE1TX1dUeVNia0E1S212Q28yaEFuN2dYU0V6R2pxQXlVMVA5VHFuTkNaMmtLVWJVNzBZVTUyV2NkZjllNUU?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-08T07:00:00+00:00", "published_display": "08 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Securities Lawsuit Alert: Biohaven Ltd. (BHVN) - Contact Levi & Korsinsky Before September 12, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPcUFnNnRVZ2I4QkkzWVIzVTdsQ19LOFhRRFk4bEZLTGU4SEVXUWFiM1lPLU10QWhMakNncFdqY2o2bU5lakkwcXZENkdmdlRsTnFIT09qVjJHemRodE1UZF9ySVc3RWEwdUotT3JTNVZ5alFuN0otNlprcEZBN01JVkZMNXYwazl6VldlRWM3b1R2VDlScy00alpwcGprYkFETEpROVg2Y1J5UzdFMkxidWRqU0ZVbUtoNUFVbjhTTUY2bVZqeW9jSDVkZl9jbm4z?oc=5", "source_name": "TMX Newsfile", "published_at": "2025-08-04T07:00:00+00:00", "published_display": "04 Aug 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to earnings forward of Biohaven Ltd. \u2013 BOATS:BHVN", "summary": "This page provides financial information for Biohaven Ltd. (BHVN), specifically focusing on its forward price-to-earnings ratio. It is hosted on TradingView, a platform offering market data, financial tools, and community features for traders and investors.", "url": "https://www.tradingview.com/symbols/BOATS-BHVN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T19:13:22", "published_display": "14 Jul 2026 19:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Research Ltd Shs Unsponsored Brazilian Depositary Receipt Repr 0.33333333 Shs", "summary": "The article focuses on the \"Price to book forward\" for Biohaven Research Ltd Shs Unsponsored Brazilian Depositary Receipt Repr 0.33333333 Shs (BHVN34) traded on B3. It displays the stock's ticker, current market status, and various financial and technical data sections available ", "url": "https://www.tradingview.com/symbols/BMFBOVESPA-BHVN34/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T01:39:04", "published_display": "14 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk (NYSE:BHVN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNYzl0WGhENFJOdFdhQUFBT3o4ZjN6RDFUNWtWbXd0RnJOSVZwT0pxamF5cFNWaTBJZTMxQThGWjFvLTIzOGU2VG5jaUhtZG5FajQtaERab29hYkZkUTNsZXVFNVJ5WTJuUTRjdHpuWHhndmgxOFV2Tl83MHBIT0pUc0NadW5uQ004N0VWZlZhRWg0UXpTUWRnVUJrUDdWbVFxRk5Gd2dn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-13T12:17:31+00:00", "published_display": "13 Jul 2026 12:17", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Biohaven Ltd. \u2013 BOATS:BHVN", "summary": "This article provides financial information for Biohaven Ltd. (BHVN), specifically its enterprise value to EBIT forward. It indicates various sections typically found on financial platforms, such as an overview, financials, news, and community features, but the core content only ", "url": "https://www.tradingview.com/symbols/BOATS-BHVN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T18:39:16", "published_display": "12 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (BHVN) Advances Key Trials Following Pipeline Progress While Valuation Still Looks Pricey", "summary": "Biohaven (BHVN) has reached two significant clinical milestones, completing enrollment for its RISE3 opakalim epilepsy trial and initiating Phase 3 testing for BHV-1300 in Graves' disease, leading to a recent surge in its stock price. Despite this positive momentum and a 51.4% 30", "url": "https://www.sahmcapital.com/news/content/biohaven-bhvn-advances-key-trials-following-pipeline-progress-while-valuation-still-looks-pricey-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T14:09:39", "published_display": "11 Jul 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Biohaven Ltd. \u2013 NYSE:BHVN", "summary": "This article presents financial information focused on Biohaven Ltd. (NYSE: BHVN), specifically its enterprise value to revenue forward ratio. It appears to be a financial data snippet from TradingView, indicating no current trading activity as the market is closed.", "url": "https://www.tradingview.com/symbols/NYSE-BHVN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T02:40:48", "published_display": "11 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BHVN News | BIOHAVEN LTD (NYSE:BHVN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTE5pRFBqVk9LODZlUWxMVXJlN3RSMllQeWFFLXdFclAyZEQxQjc5NVFod1NCMEo4VTNlQy1SN1VQR2htQW9oekx1SzVxNHVwU1NfTXFmSGtUZHh2d2s?oc=5", "source_name": "ChartMill", "published_at": "2026-07-11T00:04:00+00:00", "published_display": "11 Jul 2026 00:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership", "summary": "", "url": "https://finance.yahoo.com/m/74f0a4dc-902c-3d10-9ac6-dc1f5bc01abe/arpa-h-puts-%24160m-into.html", "source_name": "BioPharma Dive", "published_at": "2026-07-10T08:04:00+00:00", "published_display": "10 Jul 2026 08:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Biohaven\u2019s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/biohaven-bhvn-r-d-shake-061150596.html", "source_name": "Simply Wall St.", "published_at": "2026-07-10T06:11:50+00:00", "published_display": "10 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Chief Scientific Officer Bruce Car to Transition to Chief Innovation Officer", "summary": "Biohaven Pharmaceutical Holding Company Ltd. announced that Bruce Car, Ph.D., will transition from Chief Scientific Officer to Chief Innovation Officer. In his new role, Dr. Car will focus on external pipeline innovation, business development, and strategic partnerships, while al", "url": "https://www.moomoo.com/news/post/72736474/biohaven-chief-scientific-officer-bruce-car-to-transition-to-chief", "source_name": "Moomoo", "published_at": "2026-07-09T23:39:22", "published_display": "09 Jul 2026 23:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven reshuffles scientific leadership as Car steps back", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOVGxJck4xX2p4NU5nNmJ2OVYyYTRTXzlsSDd2UWFaMUdUY1ZaSTBJMGRfWHlTM0FvdGZrX0ljdmJjZWFCV09OV3Uzc3JDSVJELVF2NVE2bTVnMDFSd1p4RnAzNU9GaUptNU8zaGp3VzBuSG5sVlRtRXlzOXdJQ0RzT1J0VElEcm9JWUxFU3VzbVdQYjhhUmVURWEyRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-09T21:00:00+00:00", "published_display": "09 Jul 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janus Henderson holds 8.58M Biohaven shares (BHVN) \u2014 5.7% stake", "summary": "Janus Henderson Group Ltd. has filed an amended Schedule 13G/A, reporting beneficial ownership of 8,584,676 common shares in Biohaven Ltd. (BHVN), which constitutes a 5.7% stake as of June 30, 2026. The filing clarifies that Janus Henderson and its affiliated asset managers exerc", "url": "https://www.stocktitan.net/sec-filings/BHVN/schedule-13g-a-biohaven-ltd-amended-passive-investment-disclosure-c0dc83bc6806.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:39:47", "published_display": "09 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven announces leadership changes in discovery unit By Investing.com", "summary": "Biohaven Ltd. has announced leadership changes within its scientific discovery unit. David Pirman has been promoted to Executive Vice President and Head of Discovery, while Bruce Car is transitioning from Chief Scientific Officer to a part-time Chief Innovation Officer role. The ", "url": "https://ng.investing.com/news/stock-market-news/biohaven-announces-leadership-changes-in-discovery-unit-93CH-2593973", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T21:39:22", "published_display": "09 Jul 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Announces Scientific Leadership Transitions", "summary": "Biohaven Ltd. has announced scientific leadership transitions to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, leading internal drug-discovery. Bruce Car, Ph.D., is transitioning f", "url": "https://www.prnewswire.com/news-releases/biohaven-announces-scientific-leadership-transitions-302822263.html", "source_name": "PR Newswire", "published_at": "2026-07-09T21:12:10", "published_display": "09 Jul 2026 21:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (NYSE: BHVN) shifts CSO to innovation role, promotes discovery head", "summary": "Biohaven Ltd. (NYSE: BHVN) has announced significant scientific leadership changes. Bruce Car, Ph.D., will transition from Chief Scientific Officer to a part-time Chief Innovation Officer role, focusing on scientific initiatives and external collaborations, including those with B", "url": "https://www.stocktitan.net/sec-filings/BHVN/8-k-biohaven-ltd-reports-material-event-0e812e6f68dd.html", "source_name": "Stock Titan", "published_at": "2026-07-09T21:12:10", "published_display": "09 Jul 2026 21:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Biohaven Announces Scientific Leadership Transitions", "summary": "Biohaven Pharmaceutical Holding Company Ltd. announced significant transitions in its scientific leadership. Dr. Stephen Hoffman, Chief Medical Officer, is retiring and will be succeeded by Dr. Richard Rodgers. Additionally, Dr. Vlad Coric has been appointed as the Chief Scientif", "url": "https://www.moomoo.com/news/post/72735791/press-release-biohaven-announces-scientific-leadership-transitions?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-09T20:39:22", "published_display": "09 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (BHVN) Completes Enrollment in RISE3 Trial", "summary": "Biohaven (BHVN) has announced the completion of enrollment for its RISE3 trial, a pivotal Phase 2/3 study for opakalim in refractory focal epilepsy, with top-line results expected in the second half of 2026. The company also initiated a Phase 3 trial for BHV-1300 to treat Graves'", "url": "https://finance.yahoo.com/healthcare/articles/biohaven-bhvn-completes-enrollment-rise3-104059634.html", "source_name": "Market source", "published_at": "2026-07-09T10:40:44", "published_display": "09 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (BHVN) Is Up 5.6% After Advancing Two Late-Stage Trials in Epilepsy and Graves\u2019 Disease", "summary": "Biohaven (BHVN) has seen a 5.6% increase after advancing two late-stage trials: completing enrollment for its Phase 2/3 RISE3 trial of opakalim for refractory focal epilepsy and dosing the first patient in a Phase 3 trial of BHV-1300 for Graves\u2019 disease. These milestones highligh", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/biohaven-bhvn-is-up-56-after-advancing-two-late-stage-trials/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-08T21:39:47", "published_display": "08 Jul 2026 21:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Wall Street Is Growing More Cautious on Biohaven (BHVN)", "summary": "Wall Street is showing increased caution towards Biohaven (BHVN) due to mixed analyst sentiments. While BofA downgraded the stock and lowered its price target, citing concerns over its Kv7 epilepsy program and competitive landscape, Deutsche Bank raised its price target and maint", "url": "https://www.insidermonkey.com/blog/why-wall-street-is-growing-more-cautious-on-biohaven-bhvn-1796023/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-07-06T13:20:00", "published_display": "06 Jul 2026 13:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in BHVN Response", "summary": "This article analyzes Biohaven Ltd. (NASDAQ: BHVN) using AI models to suggest trading strategies. It highlights strong near to mid-term sentiment but a weak long-term outlook, identifying compelling upside potential due to a lack of resistance levels above the current price. The ", "url": "https://news.stocktradersdaily.com/news_release/98/Discipline_and_Rules-Based_Execution_in_BHVN_Response_070626032802_1783322882.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T03:28:00", "published_display": "06 Jul 2026 03:28", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BHVN - Biohaven Ltd Latest SEC Filings", "summary": "This article provides the latest SEC filing details for Biohaven Ltd (BHVN), including its stock performance, key financial metrics, insider and institutional ownership, and valuation ratios. The company has a market cap of $2.40 billion and shows significant institutional owners", "url": "https://finviz.com/stock?t=BHVN&ta=1&p=d&ty=lf&b=1&r=m1&page=8", "source_name": "Finviz", "published_at": "2026-07-03T22:41:52", "published_display": "03 Jul 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Shares Drop 9.8% to $14.28", "summary": "Biohaven's shares fell 9.8% to $14.28, following a downgrade from BofA to Underperform with a reduced price target of $11, citing a bearish view on the risk-reward ahead of Phase 3 data for their kv7 epilepsy drug. This contrasts with a Deutsche Bank upgrade to a $20 price target", "url": "https://intellectia.ai/news/stock/biohaven-shares-drop-98-to-1428", "source_name": "Intellectia AI", "published_at": "2026-07-03T22:41:52", "published_display": "03 Jul 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Advancing Opakalim and BHV-1300 to Pivotal Trials Change The Bull Case For Biohaven (BHVN)?", "summary": "Biohaven has advanced two key pipeline assets, opakalim for refractory focal epilepsy and BHV-1300 for Graves' disease, into pivotal trials, marking important milestones for the company's neurology and immunology pipeline. While this progress keeps the programs on track for poten", "url": "https://www.sahmcapital.com/news/content/does-advancing-opakalim-and-bhv-1300-to-pivotal-trials-change-the-bull-case-for-biohaven-bhvn-2026-07-01", "source_name": "Sahm", "published_at": "2026-07-01T19:44:00", "published_display": "01 Jul 2026 19:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out", "summary": "Bank of America Securities downgraded Biohaven Ltd. to Underperform, lowering its price target to $11 from $12. The downgrade stems from concerns about Biohaven's lead epilepsy drug, Opakalim, which is expected to face significant competition from Xenon Pharmaceuticals' azetukaln", "url": "https://www.sahmcapital.com/news/content/analyst-warns-biohavens-lead-drug-may-struggle-to-stand-out-2026-06-29", "source_name": "Sahm", "published_at": "2026-06-30T23:40:21", "published_display": "30 Jun 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven's epilepsy drug Opakalim finishes pivotal study enrollment", "summary": "Biohaven Ltd. (NYSE: BHVN) has completed enrollment in its pivotal Phase 2/3 RISE3 study for opakalim, a selective Kv7.2/7.3 activator, aimed at treating refractory focal epilepsy. Top-line results are anticipated in the second half of 2026. The company reported promising data fr", "url": "https://www.stocktitan.net/news/BHVN/biohaven-completes-enrollment-in-rise-3-pivotal-focal-epilepsy-study-p7stx3rq4msv.html", "source_name": "Stock Titan", "published_at": "2026-06-30T15:39:14", "published_display": "30 Jun 2026 15:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven completes enrollment in opakalim epilepsy trial", "summary": "Biohaven Ltd. has completed enrollment in its pivotal Phase 2/3 trial, RISE3, for opakalim, a treatment for refractory focal epilepsy, with top-line results expected in the second half of 2026. The company's stock has surged 32% in the past six months, reflecting optimism about i", "url": "https://www.investing.com/news/company-news/biohaven-completes-enrollment-in-opakalim-epilepsy-trial-93CH-4767573", "source_name": "Investing.com", "published_at": "2026-06-30T12:10:50", "published_display": "30 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven completes enrollment in focal epilepsy drug trial", "summary": "Biohaven Ltd. has completed enrollment in RISE3, a pivotal Phase 2/3 trial for opakalim, an investigational drug for refractory focal epilepsy. Top-line results for this study are anticipated in the second half of 2026. This development marks a significant step forward in the opa", "url": "https://www.streetinsider.com/Corporate+News/Biohaven+completes+enrollment+in+focal+epilepsy+drug+trial/26709571.html", "source_name": "StreetInsider", "published_at": "2026-06-30T11:10:51", "published_display": "30 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12", "summary": "BofA Securities has downgraded Biohaven Pharmaceuticals' rating from Neutral to Underperform. The firm also adjusted its price target for Biohaven, lowering it to $11 from $12. This revision reflects a more cautious outlook on the pharmaceutical company's future performance.", "url": "https://www.moomoo.com/news/post/72190363/update-bofa-securities-downgrades-biohaven-to-underperform-from-neutral-trims?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-30T11:09:45", "published_display": "30 Jun 2026 11:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target", "summary": "BofA Securities has downgraded Biohaven Pharmaceuticals' rating from Neutral to Underperform. The firm has also set a new price target of $11 for Biohaven's stock. This downgrade suggests a negative outlook on the company's future stock performance by BofA Securities.", "url": "https://www.moomoo.com/news/post/72189012/bofa-securities-downgrades-biohaven-to-underperform-from-neutral-11-price", "source_name": "Moomoo", "published_at": "2026-06-30T10:40:20", "published_display": "30 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator", "summary": "Biohaven Ltd. has announced the completion of enrollment in RISE3, a pivotal Phase 2/3 study for its selective Kv7.2/7.3 channel activator, opakalim, for refractory focal epilepsy. Top-line results are anticipated in the second half of 2026. This study aims to provide a new treat", "url": "https://www.prnewswire.com/news-releases/biohaven-completes-enrollment-in-rise-3-pivotal-focal-epilepsy-study-with-opakalim-a-selective-kv7-27-3-activator-302813944.html", "source_name": "PR Newswire", "published_at": "2026-06-30T07:30:50", "published_display": "30 Jun 2026 07:30", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (BHVN) Shares Decline Nearly 10% Amid Market Fluctuatio", "summary": "Biohaven Pharmaceuticals (BHVN) experienced a significant 9.8% stock decline on June 29, 2026, dropping to $14.28, reflecting market volatility and challenges for the clinical-stage biopharmaceutical company. The company has a low GF Score\u2122 of 30/100 and a low profitability rank,", "url": "https://www.gurufocus.com/news/8936400/biohaven-bhvn-shares-decline-nearly-10-amid-market-fluctuations?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-29T22:39:35", "published_display": "29 Jun 2026 22:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at BofA", "summary": "Biohaven Pharmaceutical shares have dropped due to concerns over its Phase 3 trial results for taldefgrobep alfa in spinal muscular atrophy (SMA). BofA Securities downgraded Biohaven from Buy to Neutral and lowered its price target to $30, citing the trial's failure to meet its p", "url": "https://www.moomoo.com/news/post/72206040/biohaven-shares-down-as-phase-3-trial-concerns-trigger-downgrade?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-29T21:10:50", "published_display": "29 Jun 2026 21:10", "sentiment": "negative", "sentiment_pct": 25, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Going On With Biohaven Stock Monday? - Biohaven (NYSE:BHVN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNNEVNTzhiZHE3MmtDdHVaMVJqOHl5V2VUTUxuZUNGcVFNYS0yR3dpbExqM0hnbjd2OE5KQmhQV29ZTndITkFWZXJFOHdTN3Vja2NsR3NSLWlqRG93SUdwUzB5RGZJQ0lsb1c3SE00UHJqM2tsZG5PMlYyNV9HcDRIN0NybmpJQ3kzb043Y3JuejRlQmJ1RW9aVHlKcjIyQ3JBZEFJcDFIcFdtRjRySFFsX1pqNWhoTkFaMGlteXBiZkpVdjN3clM1d0NCWVo?oc=5", "source_name": "Benzinga", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven's BHV-1300 targets the root cause of Graves' disease in Phase 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOMFRocTBWOUozeWpxRFhvUXhjSE55TmlNNjlrTGFLUTlNWHlUOEdFY2M1amdjZ3VPZC11YXo1NmFJYW9lMXVOY1JEZE9mVzdoRzZJWmpRZmJWR2VKMXhURVB5QWF3d1RXMXVlaU1nSDllekZQQnhUeVNTMFlScEhTbTFURTRfTUxva3F2VWlWWEp4T1RiX2kxcGRrb2xvMGJkYXFSRUM5MFVSYXNFRG1EWHlfMG1jZzE3YWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (BHVN) Climbs 14% Higher Ahead of New Clinical Trials", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOVXVFcVNvQlg2TDQ2anhEQUc3SEYxZFpNZG1kN3lGT3NJUWVNeHlTWUxsRUVSa0dVYXppaEJxSnJ4V2t4RlNQMUs2MzNOUVd6TVlSR2hCeXYxMllLWnQ5NTVrOWd1ZlB3RVJWZ0k1NDVWOURESEtEa2tFRGpwNmJQQWhjLVZHYTQ4ZC1Yb0lEMFVUT2tXY2c?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (BHVN) Climbs 12.66% Ahead of Pipeline Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQSmxoRDM4TU1pR2NIWGhjWHNCWDRvZ2JJVnZkcUdTSmVETGF6cWVPNzJCbXVaanhsSDVxQmNxaHBIanZ2RDMwZnZDMHNheEQ2ZGZVUFBnbnQ4Y0pYN1JzY2NEcWxhSW9hZlhSaWFXcy1EOXRzRThfU3B4TWZGaEtMdlZ2Yjl0WVEzNTFFOTB3WkE?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Biohaven (BHVN) the Best Stock That Have the Potential to Rise 1000%?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOR3RXZHpfY0ZNTGJYdzdPdjlpY1dOQzJIemtDMjBENG5uWmkxVUtkTUd3WjNvOWdnczNfamhMWDR1dlVUdEFUUnN1WkQ0MjNfRTBYMTZQOVNwc1dDdllhUTNOSjZoVmU2TmZRd1ZrMXVPcTROLVVTUGUzbmpxVjUydVdMX0RiTm5kbUdSaG4tOVhfZ1NZOGZ5WkhTdXN0TTRn?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Experimental brain drug from Biohaven triples glucose use in human donor brains", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQd2wtWkV0WERJZi1XRUFROEIxakN2eDlfbVRYRlpvdzBsREk4dHgtOTdlaU5pZk0tT2ViVHo4cGRjOFBDdVVmV0E0TUp5aVIwRzNieEVPVFJZQVhqYkpySXBtWF93aGtOSmhDRUg1UmZ4elBrRWVTNF9PTHNGTXdTZlJxT3BabUNFMnBIbnkwbHAyV1FxODEyVmM1SWVqLWFFZm91WU54MHNabGoxV2NTNWFVdGp1c1ptRUJROQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwJBVV95cUxORTBwNkkzd0NjamJZSkI5Mmpudndaa0thN1JndnVySDhWMnJ0WGFhWTRUMEJzb1o1aE8yMWZKQ1UzWXpmaHFrczFNb3JILWN1aWFJc3RlWkpMaWtUNGtzU3BISWRLSEJURjZZX01sZTZjQ1M1dGd6Zi1ndGxHeEdyVFFSdzRQWEJ1Z05Vdm9aRU5SY21QV3BkYldJQkVGU0M2TXhDakNzenBHYzUyc1ZpaklrYnNJT0hadmpIaVh4R1NxY0g4MWlsU24zRENlQzNBOXZKREtORW5pX0ZyWUQ3NENBNEE0RFZuc3lfdjNHZHYwT0twc29vUUFUVFJzNHc5b0FRZFEwdlRDT28?oc=5", "source_name": "PR Newswire", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNSnE1UGI2LWdPamFoX1FrdnJGLUtMVERyUVZIaFBfaC1EOUtPXzkxbEN4WXpxLU1nNGdJSWt2M1BCVjdDQVpwNVlxbWhtTVZzbjlmWGNhQzhENGpQeWNYMGJZR1JTelBOaTM3aTRXMEF1WnBOSjgzbDlMVmMyV25pSElGY0lCMU9iUVl2LWZ1ZXhVLUZTR05VOV9kdFRRZzdob2hEdXNBelhvZEZSa2dWMHJzMnZZcnY1LVVkNEFmY3JLaWhQdkcxSTdGT2tNeVJIMGtaSERwUWlPQQ?oc=5", "source_name": "PR Newswire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (NYSE: BHVN) shareholders back directors, auditors and pay plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNdGUzc3R6b1F2T2pRTkptSHhYd3RnQTRRT1QxaFd6QV9zd0ZMRnZmRUxQcEtLUUgtYnkyeEpncHZQM29nUjhZRXZDM0NMVVFSV0d2a3JnMmwzdm1DaWhlanVPaksxSlpQbVVmbHVXdHJwTGZOSXJNVnZOYmhxN1J1UVFvT0xJOU5CSFNPd2UycGRjWWZ3a01sdVpsRHFvdVgyWjUw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (BHVN) director granted 68,693 options at $9.61 strike", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOLXNaX3p4QTBjOUs3VHBzVHlRSWVURkdocGU5bGphOXVKdEt1VmhMWVQtREtrTlA2QmdCMWpWWlNIY1FNcWViLVRqaVJrQUdNak9DeWFOSTBkV196eWl3akFfT1JKU3JZZVRhS1NWby1zdjJfbG5vdFB6UVpXWkZfY0Q5LUtrOVJhN25QdHEzaFlpNGVfLV9LNzUtQWJlc0Q4M3BocFMzQlRDQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOZ3hWSDhsWWFBOHN6NTdUNEtDekNUQXlLb2JnMFdGV081YWhCNTYxOEwwNnlJdU5XdG5LeVh6VGlKbkxoTS1VelQ4cW4xZDBSSTNqUFEtLXV1eWo5bFBRWTJpTjQ0V2lyWng5NXpwbEFUYUhUWDRLS3V4MVRmNWVBaGFMOGNxU2FvaVltSjlJQ1h4NnZzNDJ5cmtaMEJ6MWIxOVItX25FWlFtd2NBOVk4?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQZC1BU1JHcWhsdmkwNzM2YkoyTjRtV1d5U2hoa3FtU2w4ZXFFaW0zYWVVcFNwME4tMHFBampOU2hNOVNua0dzdU9XX2g3bGxneUg5Yzh5NVZyZGQxTmF0Ui02Wm5kc2l2ZEhhVnBvZ2JTYzBJdXA2MExTUUd4WTAycXpJRUt2UkVJYnJzbFFxRE5YZlRmYXRuUUhHaHlYRWNBekNmeUpJTDZKd1lPSXJlU1h0R2tBWTc1RC1XWTFSRWVsNU11Yk5RZzZldWJ3TGxVZkxv?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven stock rises as obesity trial completes enrollment", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQRm84TFNJZURCUVVpNTNFWUd3TGRmZEdTREtvNHF3NEJjak1IUVRDLTI4V3BhalNKS21tel9RTTJabXcyeUl4dWFLR2w5Nk5RQWNlcFZ0WV9fTF9nNjYzN2NkcENwNE9sUmpCbVp5YV9KRmM0N2tGVGwtNU54MUdWa3NjMS1PZktSYkVBdHZPN2ZJVURkc1IyZnRxSm9qalBVREJJMlo3ZWFJOTJ4bjVBTXhJcXh4UVo1cTB2Yg?oc=5", "source_name": "Investing.com", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven (NASDAQ: BHVN) director reports gifting 34,684 shares, adds family trust", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNNFl1cXA1eXhUdl9SR04xSTQ5YUJoc1Bob2Vwbmdhd1NEVDlFSjE3WWxTbzZieF8zUzlXY3ZCZW54dVNZdUJYaGxBNzN5Sk1aTEhaNFpfTTkxZkRpdUZidTYySDQwNUZlbjFHZUtBZmN2OTRRQ3N4SS1vWDF2V0VFeDU4TUZYeThDX3ZzcXF5VE9WS2h4UXVRcTZkaFBma3d5TGdhYy1teVF4UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Ltd. (BHVN) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE55cFJ4ZVpSWEJjU01jUFRfSnVFNzlWUjloNWlQWV9Ib2ZlX19SdXlac2RtUWsydFVtdFhhbWRyYThiSnlEM3FPVWZ5dmJhWGQxTk14YzhLUQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T00:24:09+00:00", "published_display": "13 Jan 2026 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Stock Slumps After Hours As Failed Depression Study Adds To A Brutal 2025 \u2014 Retail Eyes Epilepsy And Obesity Catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxQYmJQSFZHVmRrVlJCZjREVEc0RkVsdG04Mzh3ZDhNNy1xY0hiUUN5QVVjaEFtYVlsaDN5dnJXVmZzMlVaWE9PUnEzV3hhb21LVXlLUTFDNWxjMTZmaFRJVzB4d2YtM2NKS3JHcXhMQ195RHlCdUhqTVc0QjdvWXRNbHVwXy1NUVR0SUp1ZU5DYTN6V1F6RnByQVUxZ0ZrNTBkeXIydFJJVGdUVkx4NW4tZHhzQl9ad1FVbXJDTVhkQ1Z5MXlMVk9RbEJBdS1ydVdpVzhabEhFaDh0M2ZL?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-24T08:00:00+00:00", "published_display": "24 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQcXgzWGpuYlhmbmpBMWEweWtkYWhEOFNFcXVaNTJnUFJoMW5udkNIVExyRFR0VTQ1QjRFa0F3UWRNc19VQWlFWjhLUk5WMzBPa3ZzYndZSTZiMVpiUWlQSzJFc2tSdEZGOHh2eWdhVnFPekNEc205djdpZ1JRXzdlR29Tdi1OU2dOcWFzM21sd1ZLNkhibmFtTzdZR2t0NnR0SUpaV01vREhUTUhLRG93d0poS0FHelFJM2FSY0duRG9HUmxtZUpjQzEzVHlpUGZJYkozME5SX3M4UQ?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxONTh3Mkg2aHB1LXluTDRiMzRWbzRuUE9fY0pYUU1tbExITVN6TGdtdW1UN0JOWkFQV2kzM1FQNjZEdU10bHpxbmJBZzB6YnE4WUExcHpYTW1TZGZKSDdFdUtPa1JrdlE3NzRUSmlTVk95dGN1a1l6VXp6dDFWOUx3THBISnlMbWxKWW9wY3NjNng0ZXQ3WGU2TDQzUHJHLWNucVJNblRnMmtjaGNmY1NPUmJHLTJqZmpQWm1XYzZlemN4eVZ1cjVmQzhGY0loLXpWeExpU0ZUay1Sazl3RWVobW84YVYweUJkWG92WGJXbjVpODdRRUlYSDdkYWsyVFI0RGlN?oc=5", "source_name": "PR Newswire", "published_at": "2025-11-04T08:00:00+00:00", "published_display": "04 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxQQWhCam45ekN5dksxcFJfR0RnYlpJTFJwWHM2UmFGbVhTZklzYy0zYVFuTVdqQmxXQVM0aGpwckFYV2lLZ3A1TEtxd3NHQUdmdUtseDNqYS1RUzQ0V0djTUwxQnRiTnY4NUR2V0VlMnZoek45UGxGejc1ekZWbG5DN0NWNlMwRkhzTDIxX2RRbi1yWW5lTkZ4WnpkRkU4ZWlwcTQyZ0lnSi1sX3lZVUFad0d3S2dFOE1TX1dUeVNia0E1S212Q28yaEFuN2dYU0V6R2pxQXlVMVA5VHFuTkNaMmtLVWJVNzBZVTUyV2NkZjllNUU?oc=5", "source_name": "PR Newswire", "published_at": "2025-09-08T07:00:00+00:00", "published_display": "08 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Securities Lawsuit Alert: Biohaven Ltd. (BHVN) - Contact Levi & Korsinsky Before September 12, 2025", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPcUFnNnRVZ2I4QkkzWVIzVTdsQ19LOFhRRFk4bEZLTGU4SEVXUWFiM1lPLU10QWhMakNncFdqY2o2bU5lakkwcXZENkdmdlRsTnFIT09qVjJHemRodE1UZF9ySVc3RWEwdUotT3JTNVZ5alFuN0otNlprcEZBN01JVkZMNXYwazl6VldlRWM3b1R2VDlScy00alpwcGprYkFETEpROVg2Y1J5UzdFMkxidWRqU0ZVbUtoNUFVbjhTTUY2bVZqeW9jSDVkZl9jbm4z?oc=5", "source_name": "TMX Newsfile", "published_at": "2025-08-04T07:00:00+00:00", "published_display": "04 Aug 2025 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 62, "sentiment_summary": {"positive": 14, "negative": 8, "neutral": 40, "score": 52, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 18.5, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 8.25, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 15.55, "latest_week": "2026-07-10", "one_week_move": -2.6, "four_week_move": 37.9, "twelve_week_move": 41.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.890288, "market_dynamics_buy_signal": false, "relative_strength": 13.590814, "fair_value_gap": -42.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 50.8723, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.6% over one week, +37.9% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "Stock Titan", "count": 9}, {"label": "PR Newswire", "count": 7}, {"label": "TradingView", "count": 5}, {"label": "Moomoo", "count": 5}, {"label": "Sahm", "count": 3}, {"label": "Investing.com", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 7}, {"label": "Regulatory and legal", "count": 3}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-2.6% over one week, +37.9% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to earnings forward of Biohaven Ltd. \u2013 BOATS:BHVN"}], "updated_at": "2026-07-16T00:36:58.300010+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}